Jayastu Senapati
@jayastuMD
Followers
3K
Following
37K
Media
138
Statuses
2K
Asst. Professor, Dept. of Leukemia, MD Anderson Cancer Center Houston (CMC Vellore & AIIMS ND alumnus). Tweets are my own. Vasudhaiva Kutumbakam 🇮🇳🌍🇺🇸
Houston, TX
Joined October 2013
➡️ Check out our manuscript just published in @AjHematology on Treated Secondary-AML: 673 patients, largest reported cohort.🔴 High-risk subtype: outcomes dismal, even in rare patients with fav genomics ✅ Warrants an independent prognostic designation.🔵 Ven improves outcomes in
11
41
144
🙏🏼 I am happy to share that I have joined as Asst Prof in the Dept of Leukemia at MD Anderson Cancer Center, Houston. Years of education, training & blessings from well wishers have culminated into a surreal moment of joy. Hope to strive for the best for our patients & science 🙏🏼
63
20
474
DM in Clinical Haematology (AIIMS ND) it is! Thanks to my wife, family, and friends for supporting me throughout and my mentors for believing in me. Moving on to Leukemia fellowship at MDACC Houston @MDAndersonNews.
40
7
380
What an incredible fellow's graduation night with our esteemed faculty and mentors 🥂! I am blessed & grateful to be a part of this wonderful dept for the last yr. Humbled to receive the Research fellow of the year award 🙏🏼. @DrHKantarjian @TapKadia @garciamanero @MDAndersonNews
44
4
168
Words fail to express my sincere gratitude to the amazing Dept of Leukemia @MDAndersonNews & @DrHKantarjian for giving me this opportunity. I have met some of the nicest & most inspiring people here. 🙏🏼 to God, my parents & family, & my wife @AnweshaRayS for supporting me always.
Super cheers to our super 🌟 Leukemia fellow Dr Senapati @jayastuMD who is completing Leukemia fellowship and will join us as Faculty in the Department of Leukemia 👏👏🎊🎉@MDAndersonNews .Wishing you all the BEST!!.WELCOME!! Super proud .@DrHKantarjian @garciamanero @TapKadia
30
6
115
➡️ Check out our latest paper 📃 just out in @BloodJournal analyzing the outcomes of patients with Newly Dx AML having Splicing Factor gene mutations 🧬and the impact of Venetoclax based regimens 💊 @ CDDiNardo @DrHKantarjian @garciamanero @sanamloghavi @MDAndersonNews #leusm
@MDAndersonNews #Leukemia researchers identify the use of venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed #AML | @BloodJournal .#leusm
5
22
110
Very happy to have reviewed with Prof @Kadia how to choose the right FLT3 inhibitor in patients with AML. When options increase the right choice can get tougher!. @SpringerNature
4
18
103
➡️ Check out our latest paper reviewing the treatment of CML in 2023 in @BloodCancerJnl: we discuss the latest concepts in the field focussing on the ideal option for the patient👨🏻⚕️.Honored to have authored this paper under Prof @DrHKantarjian's mentorship. @MDAndersonNews #leusm
Discussing treatment choices and endpoints in #CML: what is best for the patient in 2023?.Please check out our review just published in @BloodCancerJnl. @jayastuMD of @MDAndersonNews #Leukemia.#leusm
9
17
102
Grateful to be a part of the Leuk Dept @MDAndersonNews @DrHKantarjian 🙏🏼.✅All 6 abstracts accptd for #EHA2022. Thankful to my mentors.@GBorthakur,@NitinJainMD @NicholasShortMD,@bose_prithviraj & Dr.DiNardo for this opportunity. Elated for the @EHA_Hematology travel award #leusm
21
3
91
A profoundly treasured moment at #ASH22. Proud feeling for any @OffCMCVellore alumnus to share the frame with a legend of the field Prof @VincentRK, who knowingly and unknowingly has inspired many across the 🌎 and 🇮🇳 to take up hematology as a career and passion.
3
6
87
Finishing the wonderful and invigorating month-long inpatient rotation with the awesome @Daver_Leukemia. Learnt a lot of leukemia and even beyond! #leusm @MDAndersonNews
3
5
81
✅ A small effort highlighting the challenges in the care of pts with AML in LMICs @TheLancetHaem: many efforts are being led by Govt & Pvt groups in India to reduce the gaps in AML care. The benefits of leuk research & improving outcomes should become a more global phenomenon 🌏
A viewpoint in @TheLancetHaem to understand the hurdles of AML care in India and LMICs. This article summarises these challenges and offers a few redressals. @jayastuMD @akhilrk1989 @TribikramHemat @ Mukul Aggarwal AIIMS
7
15
82
👨🏻⚕️Looking forward to share our long term follow up data of CRLF2 rearranged Ph-like ALL @ASCO 2022, under the mentorship of @NitinJainMD. Humbled to have received the ASCO Conquer Cancer Merit Award @ConquerCancerFd 2022 🇺🇲🌍🇮🇳
16
2
79
Missing #ASH23 but Ending Leukemia! 👨🏻⚕️ December Leukemia inpatient service at @MDAndersonNews. The opportunity to help our patients, makes everyday a blessing! ☀️
1
5
77
✈ Off to Chicago for #ASCO2022. Proud to be a part of Leukemia @MDAndersonNews. Thanks to @NitinJainMD for the opportunity. Will be presenting our long term data of CRLF2 rearranged B-ALL. #leusm First time to ASCO. Wonderful feeling!
5
2
79
🚅 🚄The excitement 😃 of my first ride in the wonderful Vande Bharat express from Howrah to Puri today can only be matched by my first aeroplane ride as a kid in 2003! Way to go! @RailMinIndia @PMOIndia @AshwiniVaishnaw
3
1
73
A tribute to all those (and many others not in the collage) who made CML a better disease to have:World CML day 09/22/2021.@NitinJainMD @doctorpemm @NicholasShortMD @Daver_Leukemia @bose_prithviraj @TapKadia @FadyyHaddad
1
12
72
Two people to whom I sincerely owe my love of hematology to 🩸🙏🏻 @MathewsVikram @chepsyphilip . Such an honor and pleasure to meet @MathewsVikram (Director @OffCMCVellore) at #ASH22 and get inspired by his work and leadership.
1
5
71
➡️ Happy to present our data on the outcomes of older patients with AML who underwent SCT in CR1 after Clad-LDAC-Ven alt with HMA-Ven regimen @ASCO (and compared with other regimens). Thanks to @TapKadia @DrHKantarjian and to @ConquerCancerFd for the Merit Award (Abstract 7047).
3
8
70
📋Excited to share this review on Advanced phase CML; from biology 🧬 to therapy 💊, just published in @LeukemiaJnl. Many thanks to @NicholasShortMD for envisaging and leading this work. @DrHKantarjian @MDAndersonNews #cmlsm #leusm.
An outstanding and comprehensive review by @jayastuMD out now in @LeukemiaJnl on the pathogenesis and management of accelerated and blast phase #CML. I honestly think he has written the most definitive review on the topic to date! .👉Check it out here:
10
22
70
➡️ Check out our latest review 📰 in @Haematologica on maintenance therapy 💊 in AML: we discuss what defines a maint Rx, the niche for maint Rx, available data, latest developments and controversies. @TapKadia @ Ravandi. Early View | Haematologica
1
18
71
➡️ Check out the commentary to our paper in @BloodJournal by @pvyas_oxford: Changing treatment changing prognosis of mutations . ➡️ Our manuscript is now out in full: Venetoclax & its effects in AML with Splicing factor gene mut
2
12
65
✏️Our recent publication in @BloodJournal highlighted in @ASHClinicalNews 🔎.Venetoclax Reverses Negative Prognostic Impact of Splicing Factor Mutations for Patients with Acute Myeloid Leukemia . @ CDDinardo @MDAndersonNews @DrHKantarjian
1
11
66
@Adityaiims Aditya we assure you we will get you a bed somehow in a ward at AIIMS best suited for his illness and condition.
2
3
58
The lifestory of Prof @DrHKantarjian: an inspiring showcase of his efforts that has changed the face of leukemia therapy over the last 4 decades. Conferred today the David Karnofsky Award (highest award by @ASCO). So fortunate to learn from him and have him leading us 🙏🏼
0
9
60
👉Check out our latest paper.✅In CBF-AML, FLAG based Rx (F-IDA/F-GO) abrogates neg prognostic impact of common kinase mutations.✅PCR<0.01% during/after consolidation➡️superior survival outcomes.✅F-GO leads to better RFS than F-IDA..#leusm.@GBorthakur
0
15
55
Decitabine can prolong/attain molecular remissions and prevent relapse in CBF AML with low level PCR + after complete or attenuated cycles of FLAG based chemo. Data from MDACC.@GBorthakur .Activity of Decitabine as Maintenance Therapy in CBF AML .
13
9
54
Medicine:a field where you can never know enough; a lifetime of learning and growing,a palette of evolving science with a subtle touch of art. 14 years from starting MBBS to completion of DM, yet I feel i know so little- I guess thats what defines Science in its truest essence.
4
9
58
🙏🏻 Thank you #ASH22 for giving us the platform to showcase our work and to my mentors for their patience and support. @DrHKantarjian @MDAndersonNews
3
3
53
➡️ 👉🏼Excited to share our recent review on Antibody-Drug Conjugates in Myeloid Leukemias 🩸 recently published in @PPO_journal_lww with @doctorpemm @Daver_Leukemia.
4
13
53
➡️Check out our latest paper just published in @CCR_AACR: Ph I results of a BETi combo with AZA in a cohort of pts with R/R AML/HR-MDS (≈90% HMA & VEN exposed; 43% MECOMr) .@doctorpemm @GBorthakur @Daver_Leukemia @ KBhalla @MDAndersonNews @DrHKantarjian .
5
10
54
🏆Celebration of 1000th CAR-T cell therapy @MDAndersonNews ➡️ this is just the beginning. ✅ The future of cancer care may well lie in the optimal use of cellular therapy 🧬🩸.@NitinJainMD @doctorpemm @NeelapuSattva @AlmanzaLeukMD @ppisters #leusm #lymsm
0
4
52
Excerpt of our interview with @OncologyTimes on our paper published in @BloodJournal.
Researchers examined the potential independent impact SF gene mutations have on survival outcomes across all patients, both young and old, with #AML and across all treatment types, either intensive or low intensity. @jayastuMD @MDAndersonNews
2
1
51
🙏🏼 A very appropriate statement we need to remember everyday when we see patients and their caregivers: "Nobody cares how much you know, till they know how much you care." .Any knowledge that is obscured by arrogance or indifference has little benefit in alleviating suffering.
1
11
57
👨🏻⚕️ Finishing touches to the last inpatient rotation as a leukemia fellow. Wonderful one month with @NitinJainMD and @doctorpemm along with our amazing pharmacists, mid-levels and nurses. All of us working towards one goal ➡️ End Cancer ➡️ End Leukemia 🙏🏼 @MDAndersonNews.
👉👉👉Wonderful time finishing up inpatient rounds with our superstar Leukemia fellow MD Dr Jayastu MD .@jayastuMD on our last day of the rotation together ➡️ Grateful for Dr Jay’s brilliance, dedication, collegiality, & amazing spirit! 🙏🏾 | #leusm #endcancer
3
3
49
Promising update of Aza-Ven-Magrolimab in N/D patients with AML by @Daver_Leukemia --> near doubling of OS in TP53 mut compared to historical cohorts of TP53mut HMA-Ven treated patients. @MDAndersonNews @DrHKantarjian #ASH2022 #leusm
2
9
47
🧑⚕️Happy to share our recent work led by @NitinJainMD evaluating Nivolumab and Ibr in DLBCL-RT of CLL: promising resp. rates in a cohort of largely heavily pre-treated patients💉@wwierda @TapKadia @doctorpemm @Daver_Leukemia @PamSharmaMDPhD @JimAllisonPhD @HCC_HemeCancer #lymsm.
👉👉👉 Excited to share results of nivolumab + ibrutinib in patients with Richter Transformation | Published today in @BloodAdvances . -24 pts DLBCL RT.-Median prior Rx for CLL/RT = 3.-10/24 (42%) had a response (64% BTKi-naive; 23% BTKi-exposed) .-Median DOR 15 mos. #CLL #lymsm
1
5
42
➡️ Check out our latest paper 📃 TKI in Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL. Frontline use of BCR::ABL TKIs + chemoimmunotherapy in non-Ph ABL class fusions could lead to improved responses. @NitinJainMD.@DrHKantarjian.
2
7
46
With the curtains coming down on #ASCO2022, time for sharing some wonderful memories while gaining momentum for #EHA2022. Inspiring mentors and awe inspiring science in the fight to End Cancer!.@MDAndersonNews #leusm @ASCO
2
7
45
😇 A nice moment captured on the sidelines of the US AML/ALL focus meet. Amazing two days of learning and camaraderie!
2
1
44
➡️ Participated as panelist in the Best of ASCO/EHA AML session by @VJHemOnc chaired by @Daver_Leukemia & moderated by @jaltmanmd, C. DiNardo & @DanPollyea: discussed our abstract on outcomes of pts >60 yrs old treated on Clad/LDAC/Ven trial led by @TapKadia, who had SCT in CR1.
5
5
46
Excited to share our Phase I trial data on the combo of Milademetan, LDAC +/- Ven in R/R TP53 WT AML & ND ts-AML. We performed CyTOF & sc-proteomic analysis to study mechanisms of resistance to therapy. @ CDiNardo @ Andreeff @ MMuftuoglu @DrHKantarjian.
4
9
44
👨🏻⚕️ Wonderful fellow's lecture by Asst Prof @FadiHaddad_MD discussing the latest developments in Advanced Phase CML.➡️ Check out our reviews in @LeukemiaJnl.and @Cancers_MDPI on this challenging topic. @MDAndersonNews
0
11
43
➡️ Check out our open access paper now published in final version @Haematologica discussing the evolution of maintenace and MRD eradication strategies in AML.@TapKadia @fravandi1 @MDAndersonNews.
Maintenance therapy in #AcuteMyeloidLeukemia (AML) is a new approach towards preventing relapse. In this review, the authors comprehensively discuss the development of #AML #maintenance therapy over the last 3 decades.
0
5
43
➡️ If you are interested in T-ALL join us in Hall D #ASH23 @ 5PM today to explore the @MDAndersonNews data of HyperCVAD-Nel +/-PegAsp & Ven in F/L Rx of T-ALL.👉🏼 Promising outcomes with progressive improvisation to the Rx.👉🏼 Tolerable regimen.@NitinJainMD will be at the podium
0
5
42
➡️ Happy to share our latest publication in @TheLancetHaem on the outcomes of older pts 👴🏾👵🏻with Ph-B cell ALL treated with MiniHCVD-InO+/-Blina: 5 yr OS of 46% and PFS of 44% ✅ possibly a new benchmark in the Rx of older patients with B-cell ALL.@MDAndersonNews #leusm
Mini-HyperCVD-Inotuzumab +/- blinatumomab shows a promising 5-year OS of 46 % in newly diagnosed older patients (>/=60 years) with Ph negative B-cell ALL. Elias Jabbour @NicholasShortMD @jayastuMD.@MDAndersonNews #Leukemia.@TheLancetHaem.#leusm #ALL
4
4
41
Thanksgiving day leukemia inpatient service with Dr. Sasaki @MDAndersonNews.skybridge. Wishing everyone a very happy Thanksgiving. Thankful to all those who chose us for their cancer care.
0
2
40
➡️ Check out our poster on display today at #ASH23 (#1500).👉🏼HR CTG🧬 loses prognostic impact with InO and or Blina added to frontline HyperCVAD chemo in newly diagnosed pts with Ph-ve B-cell ALL .👉🏼 Further analysis underway . @MDAndersonNews .@ Elias Jabbour
3
10
37
Prayers for universal peace, love and enlightenment on the 160th Birth Anniversary of The Eternal Vedic Guru, Swami Vivekananda 🙏🏼
2
1
41
The phenomenal "What's new in leukemia in 2021?" talk by Prof. Kantarjian on the backdrop of ASH 2021. Concise, knowledge dense and inspiring. @MDAndersonNews @DrHKantarjian
0
1
40
Exciting best of #ASH23 in Acute Lymphoblastic Leukemia talk today Dr. Elias Jabbour today in the Dept. of Leukemia @MDAndersonNews .➡️ More effictive InO Blina based regimens in B-ALL.➡️ Ven, Nel, PegAsp in T-ALL.➡️ Fast Off CAR T Obe Cel in B-ALL. and many others
0
4
39
Some wonderful and engaging moments from San Diego at the US CAR T-cell Rx conference. honored to hear the evolution and success story of CAR T therapy from the legend himself @GruppSteve. Thanks to @NitinJainMD @NoopurRajeMD and @ Sattva Neelapu for the fabulous organisation.
1
3
36
Breaks the heart of all those doctors who sacrificed so much to alleviate the suffering of their fellow beings during this COVID-19 pandemic.@AIIMSRDA will ensure the Govt takes cognisance of the issue and the strictest punishment is meted out to him. @MoHFW_INDIA @PMOIndia.
Doctors are ready to sacrifice everything to save INDIA from COVID-19, and such a statement against the saviours is unacceptable.RDA AIIMS request Hon'ble @AmitShah Ji to put @iSunilPal immediately behind bars under Epidemic Act. He must be punished for it. #doctorsaresaviours
7
17
35
➡️ Happy to share todays posters #ASH22 .-InO for MRD clearance in B-ALL @NicholasShortMD.-Dac-Ven-Pon in Ph+myeloid leuk.-Liv elastography for InO liv tox prediction .-Predictors of InO induced VOD.👉🏼 Looking forward to tom's oral on Splice gene mut in AML ✴ Room 353 @4:45PM
4
2
35
Wonderul CART cell therapy updates by @NitinJainMD today. Talk coincides with the @Nature paper on long lasting CART cells and decade long CLL remissions at UPenn
0
5
33
🙏🏼 Blessed to be part of this wonderful Leukemia family and be mentored by the giants in the field. A memorable graduation evening as a perfect way to commemorate 2 years of fellowship. Thankful to our Chairman @DrHKantarjian and program directors @garciamanero and @TapKadia.
Reminiscing a wonderful celebration and year as another fellowship class graduates and moves on to bigger things! Congrats to all the graduates and continuing fellows. It’s been a privilege. @garciamanero @DrHKantarjian
7
2
34
💛🎥🎬 There are very few films ever made that captures the symphony and depth of poignant human emotions as the movie MASOOM (1983) does.🌟 An artistic marvel with every watch even 30 yrs later. & the music plays with your soul🎼🎵.@AzmiShabana, @ Jugal Hansraj @NaseerudinShah
6
2
34
Captivating Best of #ASH23 talk by @NitinJainMD at Dept of Leukemia @MDAndersonNews today.➡️ Time limited therapy is not the best approach for TP53 mut CLL.➡️ Exciting trials ongoing with triplets; ☀️ novel BCL2i.➡️ Ibru+Ven frontline continues to show promising PFS
0
6
33
➡️ Check out our SOHO State of the Art Review on Acute Lymphoblastic Leukemia.✅ Optimizing F/L use of InO and Blina across B-ALL🥇.✅ Pona-Blina chemo free RX in Ph+ B-ALL🏆.✅Reducing NRM in older ALL👴🏽.✅ Nel-PegAsp-Ven in F/L T-ALL💥.✅ Consolidative CART in HR and RR B-ALL💪🏽
@SocietyofHemOnc State of the art & next questions: ALL.1. F/L InO/Blina +Chemo: deep & durable resp in B-ALL. 2.⬇️chemo is prudent in older pts w/ B-ALL while optimizing InO/Blina use.3. Chemo free Pona+ Blina Rx in Ph+ B-ALL leads to 👍 long-term OS.
2
5
33
The Indian "homegrown" vaccine (COVAXIN) works great and the recent approval by W.H.O. is a welcome step. Efficacy, safety of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
0
6
31
#ASH22 is in full swing and feels great to share the frame with some of my favorite mentors and friends @MDAndersonNews @OffCMCVellore @aiims_newdelhi @HCC_HemeCancer
0
3
31
Honoured to share the frame with @ppisters of @MDAndersonNews at @PNCStadium today for the @HoustonDynamo match ⚽️! Such an amazing feeling. Thank you @MDAndersonNews for the employee appreciation pass.
1
1
30
Is the cure of CLL in sight? Wonderful and insightful ASH 2021 CLL updates by @NitinJainMD. A new era of time limted therapy unraveling for CLL.
1
1
30
➡️ Check out our latest publication just out in @BloodJournal .✅ InO is an effective MRD eradicating agent in CD22 positive B-cell ALL.#leusm.
🚨 Out in @BloodJournal P2 trial ⬇️ #Inotuzumab safe & effective in B-ALL with ➕ MRD .🔹MRD negativity 69%.🔹2-year RFS 54%.🔹2-year OS 60%. Full article ⬇️⬇️ #leusm #oncoalert @MDAndersonNews @DrHKantarjian @NicholasShortMD @NitinJainMD @jayastuMD
0
6
32
🙏🏽 Happy to be part of this large and wonderful effort led by @doctorpemm to draw up the first consensus recommendations for BPDCN diagnosis, therapy and future research considerations.@DrHKantarjian @lane_andy.@MDAndersonNews #leusm
👉👉👉Super proud to 📣 our major collaborative effort 🙌 The creation of the North American #BPDCN Consortium now out as featured content in the latest issue of @BloodJournal @ASH_hematology !! . @doctorpemm @DrHKantarjian @lane_andy .
1
3
31
What we have acheived so far and the way ahead in the field of leukemia. A must read! . @MDAndersonNews.@NitinJainMD @DrHKantarjian.The cure of leukemia through the optimist's prism
1
5
29
An enchanhting kaleidoscope of diff Indian dance forms performed by @Samskriti_TX at @MillerTheater Houston today as we reach India's 75th Independence day 🇮🇳. A sense of pride and reflection about our Nation's rich history and vivid cultural heritage! @DrSJaishankar @MEAIndia
1
1
29
Laying the roadmap for the year ahead 👉🏼 Exciting #ASCO2022 and #EHA2022 AML and ALL updates by Prof @DrHKantarjian today in the Dept of Leukemia @MDAndersonNews #leusm
0
3
26
Honored to meet in person and hear the exhilarating tale of the discovery of CALR mutation in MPN from the prolific @jyoti_nangalia at #ASH22. Eleven years (2013 ➡️ 2022) of translational research culminating into the first anti CALR mAb ✅ presented at #ASH22 plenary.
2
3
27
@freezethawed What you study in the last month matters only around 20%; knowledege accrued bedside over 3 yrs is what takes you through the examination and therafter. Almost everyone who has worked during residency knows enough to pass. So DONT FREAK OUT. Speaking for clinical branches.
0
0
27
Early morning scenes: on the way to attend rounds with Professor @DrHKantarjian and leukemia fellow @FadyyHaddad .An amazing learning experience it was. Inspired!
0
1
26
Can we eradicate MRD in CLL? How does MRD eradication portend outcomes in CLL? Some answers can be found here.
Very happy to share publication of our review article on the role of MRD in CLL with Dr Senapati @jsalwayswins of @aiims_nd #leusm #CLLsm
4
5
28
👉🏼 Looking forward to present the data on the impact of splicing factor gene mut in pts with N/D AML ➡️ what happens when you treat these pts with venetoclax cont regimens⁉️@ 4:45PM Room 353.@ Dr C. DiNardo @TapKadia @garciamanero @MDAndersonNews @MathewsVikram @VJHemOnc #ASH22.
🎥 @jayastuMD of @MDAndersonNews discusses a Phase II study of inotuzumab ozogamicin for the treatment of MRD positive B-ALL, the role of splicing gene mutations in AML & more. @ASH_Hematology #ASH22 #HemOnc #AMLsm #LeuSM #ALLsm #AMLsm
0
2
25
➡️ Happy to share todays posters #ASH22 .-InO for MRD clearance in B-ALL @NicholasShortMD.-Dac-Ven-Pon in Ph+myeloid leuk.-Liv elastography for InO liv tox prediction .-Predictors of InO induced VOD.👉🏼 Looking forward to tom's oral on Splice gene mut in AML ✴ Room 353 @4:45PM
1
5
25
So happy to have caught up with you at @ASCO and inspired by your work and research @OffCMCVellore. Sixteen years since the start of our MBBS and to many fond menories! Congratulations on your @ConquerCancerFd International Development Award 2023. @akhilrk1989 @EbyDan2007.
Congratulations @jayastuMD on your @ASCO poster, @ConquerCancerFd merit award and @MDAndersonNews Leukemia Clinical Fellow of the year! Thanks for showing me around Chicago and for being the amazing person and best friend that you are since 2007 @akhilrk1989 we missed you buddy.
2
0
27
Happy to share our new publication evaluating the outcomes of MF patients with SF3B1 mutation.@bose_prithviraj.@MDmasarova.@doctorpemm.#mpnsm
2
6
26
Despite multiple variables, disease status at ASCT remains the strongest prognostic factor in R/R Hodgkin's for post ASCT outcomes. (work done during residency days, published now). Thanks to Prof. Biju George. @dranupjdevasia @MathewsVikram .
1
3
26
D/W @VJHemOnc about our #EHA2022 abstract on impact of kinase mutations and PCR responses in CBF-AML treated with FLAG (with Gemtuzumab or Idarubicin) regimen. Looking forward to share the full data soon! Mentored by @GBorthakur . Published by @VJHemOnc
0
3
25
👉🏼Check out our new paper📄: Nelarabine as continuous inf⏳results in significantly lower central neurotoxicitiy🧠in T-cell leuk: results from a Phase 1 dose esc trial @ Prajwal Boddu @jayastuMD.@NitinJainMD @DrHKantarjian @ Varsha Gandhi @TapKadia |#leusm
1
5
25
Thank you Prof Kadia @TapKadia. So proud and honored to be working amidst the giants of leukemia care @MDAndersonNews. #ASH22 #leusm.
@jayastuMD “Bulldozing” through the audience questions after his outstanding presentation on the outcomes of Pts with #AML with splicesome mutations at the Oral abstract session #ASH22 ; @GBorthakur presiding 😂
1
2
25
🧬 With #EHA2022 🇦🇹 in full swing and me not able to attend it in person, here is a thread (6) of the abstracts I worked on that will be presented at the conference 📊. Thankful to all my mentors and the Dept of Leukemia @MDAndersonNews. @EHA_Hematology @DrHKantarjian #leusm.
2
5
23
Wonderful discussion yesterday on advances in MPN by the prolific @doctorpemm along with @mpdrc (MPN guru Dr Mesa) and Dr. Jamile Shammo. Post session d/w @doctorpemm and the team picture👨🏻⚕️.@ASCO #ASCO2022
0
4
23
Thank you @doctorpemm! Looking forward to several such discussions in the future and efforts to turn ideas into reality that should be able to ultimately help our patients and many across the world 👨🏻⚕️👩🏽🔬👨🏼💻 @MDAndersonNews #leusm.
👉👉👉Congrats 🎉🎈🎊 to our Dr @jayastuMD | Wonderful🔬 🧠 brainstorming session together today !! ➡️ thinking about future research 💡 as he completes his final day @MDAndersonNews before returning as #Leukemia faculty with us this fall ! #ASH23 #leusm #BPDCN #MPNSM #endcancer
1
1
23
Ending cancer is a global goal; bridging the gap in cancer care is paramount. To everyone @MDAndersonNews and the world over in this common fight, every small step in alleviating our patient's suffering is as important as the ultimate magic bullet.
0
2
20
Dedicated to a person who changed the trajectory of Haematology amd stem cell transplantation in India. Mammen Chandy, MD, FRACP, FRACPA: A Pioneer in India’s Bone Marrow Transplantation Services - The ASCO Post
0
5
19
👉 Check out our review 🔎 Chromosomal Instability in Chronic Myeloid Leukemia 🧬: Mechanistic Insights and Effects #mdpicancers via @Cancers_MDPI #leusm #CML
0
5
21
A detailed clinico-pathological anaysis of UCART CD123 in a patient with BPDCN. Thanks to @doctorpemm for letting me be a part of this project. Great work by @Nate_WilsonMD. @NitinJainMD @mkonople #BPDCN #leusm.
1
3
20
Very important cost analaysis data for CAR-T cells manufacturing in academic/not-for-profit initiatives. Like India has significantly brought down the cost of SCT while maintaining good outcomes, cellular therapy should be the next focus: cancer care for all, health for all!.
1
0
21
Honored to have discussed recent developments in AML and MPN/BPDCN presented at ASH 2021 with @daver and @doctorpemm on behalf of @JIPOEditors. Small progresses in leukemia sum up to significant improvements in survival!.
Dr. Jayatsu Senapati sits with Drs Naveen Pemmaraju and Naval Daver to share thoughts and inspiration from the 2021 American Society of Hematology annual meeting. @doctorpemm @Daver_Leukemia @ASH_hematology .#ASH21 #hematology #JIPO.
1
1
21
Thanks Chepsy 🙏🏽🙏🏽🙏🏽.
#ASH22 Impact of splicing gene mutations on AML outcomes by the dynamic @jayastuMD . #fantASHtic & 🔥
0
1
21
➡️ Check out our latest review on adv phase CML just published in Curr Hematologic Malignancy Reports 📃.@MDAndersonNews #leusm @NicholasShortMD. ➡️ Also check out our previous comprehensive review on pathogenesis & Rx of adv phase CML in @LeukemiaJnl 📰.
New comprehensive review by @NicholasShortMD, @JayastuMD and Dr. Elias Jabbour of @MDAndersonNews #Leukemia discusses state-of-the-art management of advanced phase #CML. #leusm
1
1
20
MD Anderson Cancer Center ranked the best cancer hospital in the world. A moment of pride and a feeling of gratitude. @MDAndersonNews.@NitinJainMD @doctorpemm @bose_prithviraj @FadyyHaddad.@Dnrbr.Oncology
0
1
20
🙏🏼🙏🏼🙏🏼 Sincere thanks to @DrHKantarjian @garciamanero @TapKadia for your leadership and mentorship towards the comprehensive and most amazing Leukemia Fellowship Program @MDAndersonNews. @FadiHaddad_MD @AlmanzaLeukMD @AlexBataller @DesikanSai #ASH22 #leusm.
So great to see the fellows back in person at #ASH22 after a couple of years of virtual attendance! @garciamanero @DrHKantarjian
0
5
30